Back to top
more

CONMED (CNMD)

(Delayed Data from NYSE)

$54.67 USD

54.67
552,572

+1.29 (2.42%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $54.66 -0.01 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (76 out of 244)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why You Should Retain McKesson (MCK) Stock for Now

by Zacks Equity Research

McKesson (MCK) is gaining from strong segmental performance and solid prospects in the pharmaceutical and medical supplies distribution market. However, rising pricing pressure remains a concern.

Zacks Equity Research

Here's Why You Should Hold on to Varian (VAR) Stock for Now

by Zacks Equity Research

Varian (VAR) gains from Oncology unit, deals with weakness in the Proton Therapy segment.

Zacks Equity Research

Here's Why You Should Hold on to Pacific Biosciences Stock

by Zacks Equity Research

Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, stiff competition remains a woe.

Zacks Equity Research

Here's Why You Should Hold on to Surmodics (SRDX) Stock Now

by Zacks Equity Research

Surmodics (SRDX) is gaining from continued strength at Medical Devices unit and persistent efforts to boost R&D functionalities. However, weak performance at Surmodics' IVD unit remains a concern.

Zacks Equity Research

Here's Why You Should Hold on to OPKO Health (OPK) Stock Now

by Zacks Equity Research

OPKO Health (OPK) continues to gain from RAYALDEE and BioReference platforms, and focus on R&D despite operating losses.

Zacks Equity Research

Haemonetics Launches TEG 6s PlateletMapping Assay Cartridge

by Zacks Equity Research

The global commercial availability of the cartridge is likely to bolster Haemonetics' (HAE) TEG portfolio.

Zacks Equity Research

Tandem Diabetes Gets Canadian Nod for t:slim X2 Insulin Pump

by Zacks Equity Research

This regulatory clearance is expected to accelerate Tandem Diabetes' (TNDM) global pump shipments and expand its customer base.

Zacks Equity Research

Here's Why You Should Hold on to Masimo (MASI) Stock Now

by Zacks Equity Research

Masimo (MASI) raises 2019 revenue and EPS guidance.

Zacks Equity Research

Here's Why You Should Retain PRA Health (PRAH) Stock Now

by Zacks Equity Research

PRA Health (PRAH) is gaining steadily from expansion in international markets, solid 2019 outlook and growing CRO industry. However, escalating direct costs remain a woe.

Zacks Equity Research

Here's Why Conmed (CNMD) is a Great Momentum Stock to Buy

by Zacks Equity Research

Does Conmed (CNMD) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Cooper Companies' CVI Unit Gets FDA Nod, To Boost Eye Health

by Zacks Equity Research

Cooper Companies' (COO) CVI Unit has receives FDA approval for its MiSight 1 day contact lens, which complements its commitment to eye health innovation.

Zacks Equity Research

Here's Why You Should Hold on to Becton, Dickinson Stock Now

by Zacks Equity Research

Becton, Dickinson (BDX) expects tariffs to impact its bottom line in first-quarter fiscal 2020.

Zacks Equity Research

Here's Why You Should Hold on to PerkinElmer Stock for Now

by Zacks Equity Research

PerkinElmer (PKI) is gaining steadily from the core Diagnostics segment, prudent acquisitions and margin expansion. However, forex volatility remains a concern.

Zacks Equity Research

BD's Onclarity HPV PMA Submission to Boost Women's Health

by Zacks Equity Research

Becton, Dickinson (BDX) offers a wide range of next-generation solutions in the field of cervical, ovarian and breast cancer.

Zacks Equity Research

Here's Why You Should Hold Cooper Companies (COO) Stock Now

by Zacks Equity Research

Cooper Companies (COO) is gaining traction from expansion in international markets, robust product portfolio across segments and prudent acquisitions. However, forex continues to remain a concern.

Zacks Equity Research

NextGen's Medfusion Buyout to Improve Patient Experience

by Zacks Equity Research

NextGen (NXGN) showcases new capabilities and services for its flagship NextGen Enterprise platform.

Zacks Equity Research

Dentsply (XRAY) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

Dentsply (XRAY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Here's Why Conmed (CNMD) is a Great Momentum Stock to Buy

by Zacks Equity Research

Does Conmed (CNMD) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Conmed (CNMD) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Conmed (CNMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

CONMED (CNMD) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

CONMED's (CNMD) Q3 earnings gain from higher revenues, solid segmental performance and margin expansion. However, high long-term debt remains a concern.

Zacks Equity Research

Conmed (CNMD) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Conmed (CNMD) delivered earnings and revenue surprises of 10.71% and 2.32%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Conmed (CNMD) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Here's Why You Should Hold on to CONMED (CNMD) Stock for Now

by Zacks Equity Research

CONMED (CNMD) raises 2019 revenue and earnings per share guidance.

Zacks Equity Research

XRAY vs. CNMD: Which Stock Is the Better Value Option?

by Zacks Equity Research

XRAY vs. CNMD: Which Stock Is the Better Value Option?

Zacks Equity Research

Here's Why You Should Retain HMS Holdings (HMSY) Stock For Now

by Zacks Equity Research

HMS Holdings (HMSY) is gaining traction from growing PI and TPM analytical services as well as robust margins despite intense competition.